

13 Jul 2021

Bristol-Myers Squibb International Corporation

Email: Clinical.Trials@bms.com

Chaussée de la Hulpe 185

Brussels, Belgium

1170

EudraCT Number: 2018-001070-20
Sponsor Protocol Number: CA224-061

A Randomized, Active-Controlled, Open-Label, Phase 2 Clinical Trial of BMS-986213, in Combination with Various Standard-of-Care Therapeutic Regimens, in Participants with Recurrent, Locally Advanced, or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction (GEJ) Adenocarcinoma

Trial 2018-001070-20 was withdrawn with 0 patients enrolled. As such no results are reported.